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Abstract
We report a case of pure squamous cell carcinoma involving the prostate and urinary bladder and describe the
diagnostic dilemmas that we faced in trying to determine its origin. The patient was diagnosed ten years ago with
prostatic adenocarcinoma treated with radioactive seed implantation. During the last year he also underwent a
TURP procedure for urinary obstruction complicated by multiple infections. Postsurgery, the patient developed
colo-urethral fistula and decision to perform cystprostatectomy was taken. Excision illustrated a tumor mass
replacing the entire prostate that microscopically proved to be squamous cell carcinoma. The challenge that we
encountered was to determine its origin, the possibilities being divergent differentiation from adenocarcinoma
post radiation therapy, de novo neoplasm or urothelial carcinoma with extensive squamous differentiation. Our
literature review showed also that the etiology of prostatic squamous carcinoma is still unclear. We present our
approach in an attempt to solve this dilemma.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2014237929511762.
Background
Squamous cell carcinoma of the prostate is a rare entity,
representing less than 1% of all prostate carcinomas.
About half of the cases arise after endocrine or radiation
therapy for adenocarcinoma. However, cases occurring
“de novo”, in patients with no history of prostatic dis-
ease have also been reported. This finding points toward
multiple etiologies for this disease. It is hypothesized
that squamous differentiation in prostate cancer has an
origin in the urothelial lining of the prostatic urethra or
periurethral ducts. It is also speculated that it can be
derived from pluripotent stem cells capable of multidir-
ectional differentiation.
Morphologically, squamous differentiation in prostate
cancer can be encountered in pure form or associated
with adenocarcinoma, urothelial carcinoma or sarcoma.
Given its multiple possible origins, a decision as to
whether the squamous component develops through
divergent differentiation from adenocarcinoma following
treatment, represents squamous differentiation of a tran-
sitional cell carcinoma, or is a pure second prostatic
malignancy can be very challenging.
Our literature review shows that the etiology of squa-
mous differentiation in prostate cancer is not well
defined. Understanding the biology of this tumor might
help to develop more efficient therapies for this aggres-
sive malignancy with a poor prognosis. We describe our
findings and approach of this case to help pathologists
encountering this unusual prostatic neoplasm.
Case Presentation
The patient is a 77 year old male with a history of pros-
tate cancer for which he was treated with brachytherapy
(radiation seeds) 10 years ago. Patient had also a trans-
urethral resection of prostate due to urinary obstruction
complicated by multiple tract infections one year prior
to his current presentation. At present, patient was
admitted for decreased urinary output. Laboratory work
up revealed a creatinin level of 10 mg/dl, with metabolic
acidosis, thought to be secondary to acute kidney injury.
Computer tomography imaging studies showed bilateral
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hydronephrosis grade 2, with obstruction of the ureters
at the uretero-vesicle junction for which percutaneous
nephrostomy tubes were placed. A cystourethrogram
was also performed and revealed colo-urethral fistula in
the region of the prostatic urethra, extending to the rec-
tum. The bladder lumen was irregular and small, corre-
sponding to thickened bladder wall seen on CT. Patient
was taken to surgery for cystprostatectomy, ileal conduit
and repair of the recto- urethral fistula.
The cystprostatectomy specimen was composed of a
portion of prostate (4.2 × 2.7 × 2.5 cm), urinary bladder
(7.5 × 5 cm) and the surrounding fat. The entire pro-
static gland was replaced by a white firm irregular
tumor mass. The bladder mucosa was very congested,
diffusely irregular but no mucosal growths or luminal
masses were present. The thickness of the bladder wall
ranged from 0.5 to 1.0 cm.
Microscopic sections from the prostate showed an
infiltrating tumor mass forming nests and cords (Figure
1A). No benign prostatic glands were identified. Cytolo-
gically, the cells were large, cohesive, with abundant
glassy eosinophilic cytoplasm and well defined cell bor-
ders. Keratinization was noted (Figure 1B). The tumor
showed focal necrosis (Figure 1C). Areas with less differ-
entiated cells with high grade nuclei infiltrating singly
into the stroma were identified (Figure 1D). The mor-
phological appearance was compatible with poorly dif-
ferentiated squamous cell carcinoma. No other
differentiation (adenocarcinoma or urothelial carcinoma)
was seen. The tumor replaced the entire prostate,
extending into seminal vesicles, periprostatic and perive-
sicle soft tissue (Figure 2A). Lymphovascular (Figure 2B)
and perineural (Figure 2C) invasion were present. There
were also areas of necrosis with calcifications consistent
Figure 1 1A) Infiltrating tumor mass forming nests and cords. 1B) Large, cohesive cells, with abundant glassy eosinophilic cytoplasm and
well defined cell borders; focal keratinization. 1C) Focal tumor necrosis. 1D) Poorly differentiated cells with high grade nuclei infiltrating singly
into the stroma.
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with therapy effect (Figure 2D). Sections from the urin-
ary bladder wall revealed inflamed and mainly denuded
transitional mucosa with underlying granulation tissue.
Where present, the urothelium was hyperplastic with
focal frond-like proliferation. Although, cytologically, the
urothelial cells were slightly enlarged, the nuclear to
cytoplasmic ratio was maintained and the nuclear polar-
ity was preserved (Figure 3A). This degree of atypia was
less than that of the tumor cells and was considered to
represent reactive changes, secondary to the inflamma-
tory process. No areas of high grade urothelial carci-
noma were identified. The lamina propria and detrusor
muscle of the bladder were infiltrated by the squamous
cell carcinoma (Figure 3B) that also extended, focally,
into the urothelial mucosa (Figure 3C). Immunohisto-
chemistry studies, using a battery of prostate specific
antibodies, showed viable neoplastic cells staining posi-
tive for racemace/AMACR (Figure 4A) and negative for
Prostate specific antigen (PSA), Prostate specific mem-
brane antigen (PSMA), Prostate specific acid phospha-
tase (PSAP) and P501S (553-amino acid protein that is
localized to the Golgi complex and expressed in both
benign and neoplastic prostate tissues). Interestingly,
AMACR also stained the endothelial cells in the vessels
adjacent to the tumor (Figure 4B).
A final diagnosis of squamous cell carcinoma involving
the prostate and urinary bladder was rendered. The ques-
tion that arose was whether the squamous carcinoma
developed through divergent differentiation from prostatic
adenocarcinoma following treatment, represented squa-
mous differentiation of an urothelial carcinoma, or it was
the second primary prostatic malignancy in this patient.
Discussions
Squamous cell carcinoma of the prostate is a rare entity,
with an incidence of 0.6-1% of all prostatic malignancies
Figure 2 2A) Tumor extending into seminal vesicles. 2B) Lymphovascular invasion. 2C) Perineural invasion. 2D) Areas of necrosis with
calcifications consistent with therapy effect.
Arva and Das Diagnostic Pathology 2011, 6:46
http://www.diagnosticpathology.org/content/6/1/46
Page 3 of 8
and its etiology is not yet well understood. In about 50%
of the cases it arises in the settings of previous radiation
or hormonal treatment for prostatic adenocarcinoma
but also occurs in the absence of prior treatment. It is
believed that the squamous component develops from
squamous metaplasia of acini and ductal elements. Non-
neoplastic squamous metaplasia is frequently seen in the
prostate associated with chronic inflammation or infarc-
tion. In addition, malignancies such as hormonal or
radiation-treated prostatic adenocarcinoma or urothelial
carcinoma can show extensive squamous metaplasia. It
has also been hypothesized that it could derive from
pluripotent stem cells capable of multidirectional
differentiation.
Mott proposed strict criteria for the diagnosis of pure
primary squamous cell carcinoma: (1): clearly malignant
features including disorganized growth pattern, cellular
anaplasia, invasion; (2): features of squamous differentia-
tion including keratinization, presence of squamous
pearls or distinct intercellular bridges; (3): lack of gland-
ular/acinar component; (4): no prior estrogen therapy;
(5): the absence of primary squamous cancer elsewhere.
Figure 3 3A) Hyperplastic urothelium with focal frond-like proliferation. The urothelial cells were slightly enlarged but the nuclear to
cytoplasmic ratio was maintained and the nuclear polarity was preserved. 3B) Squamous cell carcinoma infiltrating lamina propria and detrusor
muscle. 3C) Squamous cell carcinoma extending, focally, into the urothelial mucosa.
Figure 4 4A) Viable neoplastic cells staining positive for AMACR. 4B) Endothelial cells in the vessels adjacent to the tumor showing focal
nuclear AMACR positivity.
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We identified in the English literature 66 cases of
prostate cancer with squamous differentiation. We initi-
ally classified them as either pure squamous cell carci-
noma or adenosquamous carcinoma and then each of
these two categories was subdivided into cases occurring
de novo and cases following therapy for a previously
diagnosed prostatic adenocarcinoma (Table 1). Our
review of the literature showed that the squamous com-
ponent was associated with an adenocarcinoma compo-
nent in 60% of the patients (39 cases, columns one and
two). There were 27 patients with pure prostatic squa-
mous cell carcinoma (columns three and four). In about
50% of the cases, the squamous differentiation occurred
in patients that were previously treated for prostatic
adenocarcinoma (35 cases, columns one and three). In
the remaining 31 cases (columns two and four), squa-
mous carcinoma occurred de novo. Within the cases
with prior diagnostic of adenocarcinoma, there were 28
patients with adenosquamous carcinoma (column one)
but only 7 (column three) with pure squamous
carcinoma.
In most of the cases the diagnosis was made on biopsy
or TURP specimens and the criteria set by Mott were
followed. In the series of 33 cases of prostate adenocar-
cinoma with squamous differentiation reported by
Parwani [1], there were 8 cases of pure squamous carci-
noma (3 cases occurring after treatment of adenocarci-
noma and 5 “de novo” cases). To rule out another
urological primary malignancy, in all these patients, the
bladder was examined cystoscopically and in addition, in
one instance, cysprostatectomy was performed which
showed no evidence of bladder tumor (Table 2). Nabi
[2], Mohan [3] and Rahmanou [4] also excluded another
source for squamous cell carcinoma involving the pros-
tate based on a normal cystoscopy exam (Table 2). The
patient reported by Okada [5] underwent transurethral
biopsy with no evidence of vesicle or urethral malig-
nancy (Table 2). In addition to the case presented by
Parwani [1], we identified just one more situation,
described by Sarma [6], in which the diagnosis was
made after cystprostatectomy procedure. Similar to our
patient, no definite site of origin such as urethra or peri-
urethral ducts could be ascertained. Grossly, the bladder
mucosa was intact and microscopic sections showed
neoplastic cells in the subepithelial tissue with normal
overlying urothelium. In conclusion, most of the authors
assumed a prostatic origin based on a normal cysto-
scopy exam. If cystectomy was performed, lack of altera-
tions (in situ or invasive carcinoma) in the transitional
lining of the urinary bladder or prostatic urethra, as well
as absence of continuity between the squamous neoplas-
tic component and the urothelial mucosa, suggested the
prostate as being the source of carcinoma.
However, even after the pathologist recognizes the
prostate as the organ of origin, it is still unclear if pro-
static squamous carcinoma represents a de novo malig-
nancy or develops from adenocarcinoma following
treatment. In our literature review, we found 35 patients
treated hormonally or with radiation therapy for pro-
static adenocarcinoma that developed subsequently
a squamous component (columns 1 and 3 of table 1).
Seven of them had pure squamous carcinoma (20%),
whereas in the remaining 28 cases (80%), the squamous
component was associated with classic adenocarcinoma
(adenosquamous carcinoma). This bias suggests that
patients treated for previous pure prostatic adenocarci-
noma have a propensity to develop squamous differen-
tiation in association with adenocarcinoma and the
squamous component represents most probably diver-
gent differentiation of the adenocarcinoma under treat-
ment pressure rather than a second primary prostatic
malignancy.
Regardless of its origin, the symptoms of squamous
carcinoma of the prostate are usually those of prostatism
due to outlet obstruction. The average age of onset is
68 years, ranging from 42 to 86. In those cases where the
Table 1 Classification of patients with squamous cell carcinoma involving the prostate
Adenosquamous carcinoma Pure squamous cell carcinoma
After treatment of adenocarcinoma De novo After treatment of adenocarcinoma De novo
18 cases, Parwani [1] 7 cases, Parwani [1] 3 cases, Parwani [1] 6 cases, Kanthan [10]
6 cases, Bassler [9] 4 cases, Bassler [9] 1 case, Miller [11] 5 cases, Parwani [1]
2 cases, Wernert [12] 1 case, Mohan [3] 2 cases, Nabi [2]
1 case, Braslis [13] 1 case, John TT [14] 2 cases, Little [15]
1 case, Devaney [8] 1 case, Rahmanou [4] 1 case, Wernert [12]
1 case, Okada [5]
1 case, Sarma [6]
1 case, Uchibayashi [16]
1 case, Di Pietro [17]
Total 28 cases 11 cases 7 cases 20 cases
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squamous carcinoma followed radiation or hormonal
treatment for adenocarcinoma, the time elapsed varies
from 3 months up to 10 years. Our patient developed
squamous cell carcinoma 10 years post radiation. Clinical
features pointing towards the diagnosis of squamous cell
carcinoma include low serum PSA and acid phosphatase
levels, high level of squamous carcinoma antigen and
osteolytic bone metastasis. Histologically, the degree of
differentiation is moderate in most of the cases. If
admixed with adenocarcinoma, the squamous component
ranges from 5 to 95%. Gleason grading system is not
used for squamous component. The morphology (ade-
nosquamous versus pure squamous cell) does not have
any prognostic significance.
In many of reported cases, tumor cells stained positive
for high molecular cytokeratin (34betaE12) and were
negative for PSA and PSAP. We performed immunohis-
tochemistry studies using multiple prostate specific anti-
bodies. The rationale was to identify if the tumor cells
in the poorly differentiated areas, that could not be
readily classified as squamous or adenocarcinoma,
retained the phenotype of prostatic glandular cells with
positive staining for any of the antibodies that were
used. In concordance with prior reports, the neoplastic
cells were negative for PSA, PSAP, PSMA, P501S but
showed cytoplasmic staining with AMACR. This immu-
nohistochemistry profile is however not useful for diag-
nosis since the tumor cells, despite the fact that they
have prostatic origin, lose the reactivity for prostate spe-
cific antibodies due to their squamous differentiation.
The positivity for AMACR is also not helpful because
this marker has been reported to be positive in urothe-
lial carcinoma, which could exhibit squamous differen-
tiation as well.
Surprisingly, endothelial cells also demonstrated weak
racemase reactivity. Wei Li [7] proved that high
AMACR in the cytoplasm of hepatocellular carcinoma
tumor cells was significantly associated with venous
invasion, suggesting an important role of this enzyme in
tumor invasiveness. The exact mechanism of venous
invasion remains unclear, but active neovascularization
is likely to play an important role.
Molecular studies showed that squamous malignant
cells can be either diploid (one case of adenosquamous
carcinoma reported by Devaney [8], with well differen-
tiated squamous component), or aneuploid or tetraploid
(one case of adenosquamous carcinoma reported by
Bassler [9] with moderately differentiated squamous
component). This disparity is probably related to the
degree of differentiation.
Squamous cell carcinoma of the prostate has a worse
prognosis than conventional adenocarcinoma, with an
average survival after diagnosis of 1 to 24 months. Ther-
apeutic modalities are limited, and surgery or non-
operative methods of treatment (radiation, chemo or
hormonal therapy) proved to be ineffective. The resis-
tance of the neoplasm to anti-androgen drugs is well
documented and goes along with an origin from the
pluripotent cells lining the prostatic ducts. A better
understanding of the biology of this tumor might help
in the development of more efficient therapy.
Conclusions
Our patient is the eighth case of pure squamous carci-
noma occurring in a patient treated for prior prostatic
adenocarcinoma. These cases are the most challenging
since oftentimes large tumor volume replaces architec-
tural landmarks and it is difficult to decide if the tumor
originates from the prostate or it extends from the urin-
ary bladder into the periurethral/bladder neck tissue.
The diagnosis is also complicated by the fact that no
residual adenocarcinoma is seen and sometimes even
Table 2 Specimen type and diagnostic modalities to exclude other urological origin in patients with pure squamous
cell carcinoma involving the prostate
Reference Number of
patients
Specimen type Procedures to exclude other urological origin
Parwani [1] 8 Prostate biopsy/TURP/prostatectomy/
cystprostatectomy
• Normal cystoscopy for 7 patients
• Cystprostatectomy for 1 patient, with no gross or microscopic
evidence of bladder tumor
Kanthan [10] 6 Prostate biopsy/TURP None
Nabi [2] 2 Prostate biopsy/TURP Normal cystoscopy in both patients
Mohan [3] 1 TURP Normal urethroscopy, and cystoscopy
John TT [14] 1 TURP None
Rahmanou [4] 1 Prostate biopsy Normal cystoscopy
Okada [5] 1 Prostate biopsy Transurethral biopsy with no evidence of vesicle or urethral
malignancy
Sarma [6] 1 Cystprostatectomy Cystprostatectomy with no gross or microscopic evidence of bladder
tumor
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benign prostatic glands are scant or absent due to prior
TURP procedure.
In these instances we proposed the following algo-
rithm in the work-up of similar cases (Figure 5).
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
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